Carl Hansen, AbCellera CEO

Look­ing for the next mR­NA break­through, Mod­er­na taps Ab­Cellera in mys­te­ri­ous an­ti­body dis­cov­ery deal

Mod­er­na’s suc­cess with its Covid-19 vac­cine has bust­ed the dam open on a range of po­ten­tial mR­NA ther­a­peu­tics — and now the biotech is push­ing to keep the cut­ting edge in-house. A new part­ner­ship with stand­out an­ti­body dis­cov­ery out­fit Ab­Cellera could help keep the ball in the com­pe­ti­tion’s court.

Mod­er­na will part­ner with an­ti­body play­er Ab­Cellera on up to six undis­closed tar­gets for a range of mR­NA-en­cod­ed drugs har­vest­ed from Ab­Cellera’s bustling dis­cov­ery plat­form, the com­pa­nies said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.